Ipsen (IPSEY) announced the European Commission has approved Kayfanda or odevixibat under exceptional circumstances for the treatment of cholestatic pruritus in Alagille Syndrome in patients aged 6 months or older. Kayfanda is a once-daily non-systemic ileal bile acid transport inhibitor.
Kayfanda is known in ALGS as Bylvay outside of the European Union. Under the brand name of Bylvay, it was approved in the E.U. as the first drug treatment option for all types of progressive familial intrahepatic cholestasis in patients aged 6 months or older.
Ipsen has also received E.U. approval for Iqirvo or elafibranor for Primary Biliary Cholangitis.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.